Lymphoma Clinical Trials in Houston

Showing 201-220 of 467 trials

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

NCT04745234

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory

Kyowa Kirin, Inc.34 participantsStarted Aug 2021

Duarte, California, United States • Irvine, California, United States • Stanford, California, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

NCT02445248

This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.

Diffuse Large B-cell Lymphoma (DLBCL)

Novartis Pharmaceuticals115 participantsStarted Jul 2015

San Francisco, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +23 more locations

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Lymphoma Trials in Other Cities

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

Other Conditions in Houston